Advertisement

Journal of Genetic Counseling

, Volume 26, Issue 3, pp 548–555 | Cite as

Prevalence and Characteristics of Patients with Suspected Inherited Renal Cell Cancer: Application of the ACMG/NSGC Genetic Referral Guidelines to Patient Cohorts

  • Hong Truong
  • Sarah E. Hegarty
  • Leonard G. Gomella
  • William K. Kelly
  • Edouard J. Trabulsi
  • Costas D. Lallas
  • Veda N. Giri
Original Research

Abstract

Patients with suspected hereditary renal cell cancer (RCC) are under-referred for genetic evaluation. Characterizing the prevalence and characteristics of suspected inherited RCC is a crucial step toward advancing personalized, genetically-based cancer risk management for patients and their families. To evaluate the prevalence and characteristics of suspected inherited RCC syndromes based on consensus criteria, we performed a cross-sectional analysis of patients with a diagnosis of RCC in SEER (2001–2011, n = 105,754) and in our institutional cancer registry (2004–2013, n = 998). Consensus criteria for referral of patients with RCC for genetic evaluation from the American College of Medical Genetics and Genomics and National Society of Genetic Counselors (ACMG/NSGC) were applied to the two cohorts. The associations between meeting referral criteria with demographic characteristics were assessed with chi-square tests. Overall, 24.0 % of the SEER cohort and 33.7 % of our institutional cohort met ACMG/NSGC referral criteria for genetic counseling. While white patients more commonly met early onset clear cell RCC criteria, black patients met papillary RCC criteria at twice the rate of whites in both cohorts (p < 0.0001). As many as 1 in 5 individuals with RCC meet referral criteria for genetic evaluation based on newly emerging guidelines, with differences in pathology noted by race. Prospective genetic testing studies utilizing emerging referral guidelines should help to refine the genetic spectrum of inherited kidney cancer. This study supports efforts to increase awareness of referral of patients with RCC for genetic counseling particularly among urologic providers.

Keywords

Kidney cancer Genetic counseling Race Hereditary cancer syndromes 

Notes

Acknowledgments

This project was supported by institutional funding from Sidney Kimmel Cancer Center of Thomas Jefferson University. We would like to thank Fran Guiles from the Thomas Jefferson University Hospital cancer registry staff for data collection. Veda N. Giri and Hong Truong had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Compliance with Ethical Standards

Conflict of Interest

Hong Truong, Sarah E. Hegarty, Leonard G. Gomella, William K. Kelly, Edouard J. Trabulsi, Costas D. Lallas, and Veda N. Giri declare that they have no conflict of interest.

Human Studies and Informed Consent

This study does not include human subjects. All data were abstracted from institutional and national cancer registries which did not contain any patient identifying information. The study was IRB-approved at Thomas Jefferson University.

Animal Studies

This article does not contain any studies with animals performed by any of the authors.

References

  1. American Cancer Society: Targeted Therapies for Kidney Cancer. Cited April 29, 2016. Available at: http://www.cancer.org/cancer/kidneycancer/detailedguide/kidney-cancer-adult-treating-targeted-therapy.
  2. Benusiglio, P. R., Giraud, S., Deveaux, S., Méjean, A., Correas, J.-M., Joly, D., et al. (2014). Renal cell tumour characteristics in patients with the Birt-Hogg-Dubé cancer susceptibility syndrome: a retrospective, multicentre study. Orphanet Journal of Rare Diseases, 9(1), 163. doi: 10.1186/s13023-014-0163-z.CrossRefPubMedPubMedCentralGoogle Scholar
  3. Centers for Disease Control and Prevention. (2014). Public health genomics knowledge base version 1.0: Genomic application toolkit. Available at: https://www.cdc.gov/genomics/implementation/toolkit/tier1.htm. Accessed 15 May 2016.
  4. Chow, W. H., Shuch, B., Linehan, W. M., & Devesa, S. S. (2013). Racial disparity in renal cell carcinoma patient survival according to demographic and clinical characteristics. Cancer. doi: 10.1002/cncr.27690/full.Google Scholar
  5. Choyke, P. L., Glenn, G. M., Walther, M. M., Patronas, N. J., Linehan, W. M., & Zbar, B. (1995). Von Hippel-Lindau disease: genetic, clinical, and imaging features. Radiology, 194(3), 629–642.CrossRefPubMedGoogle Scholar
  6. Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., et al. (2015). Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International journal of cancer. Journal International Du Cancer, 136(5), E359–E386. doi: 10.1002/ijc.29210
  7. Genetics of Kidney Cancer (Renal Cell Cancer)–Health Professional Version (PDQ®). (2016) Cited April 29, 2016. Available at: http://www.cancer.gov/types/kidney/hp/kidney-genetics-pdq#link/_586_toc.
  8. Hampel, H., Bennett, R. L., Buchanan, A., Pearlman, R., Wiesner, G. L., Guideline Development Group, American College of Medical Genetics and Genomics Professional Practice and Guidelines Committee and National Society of Genetic Counselors Practice Guidelines Committee. (2015, January). A practice guideline from the American College of Medical Genetics and Genomics and the National Society of genetic counselors: referral indications for cancer predisposition assessment. Genetics in Medicine: Official Journal of the American College of Medical Genetics. doi: 10.1038/gim.2014.147
  9. Howlader, N., Noone, A. M., Krapcho, M., & Garshell, J. (2013). SEER cancer statistics review, 1975–2010. Based on November 2012 SEER data submission, posted to the SEER web site, April 2013. Bethesda (MD).Google Scholar
  10. Kara, O., Andrade, H. S., Zargar, H., Akca, O., Maurice, M. J., Caputo, P. A., et al. (2016). Race effects on pathological and functional outcomes after robotic partial nephrectomy in a single academic tertiary care center. J Robotic Surgery. doi: 10.1007/s11701-016-0562-3.PubMedGoogle Scholar
  11. Kiuru, M., Launonen, V., Hietala, M., Aittomäki, K., Vierimaa, O., Salovaara, R., et al. (2001). Familial cutaneous leiomyomatosis is a two-hit condition associated with renal cell cancer of characteristic histopathology. The American Journal of Pathology, 159(3), 825–829. doi: 10.1016/S0002-9440(10)61757-9.CrossRefPubMedPubMedCentralGoogle Scholar
  12. Lehtonen, H. J. (2011). Hereditary leiomyomatosis and renal cell cancer: update on clinical and molecular characteristics. Familial Cancer, 10(2), 397–411.CrossRefPubMedGoogle Scholar
  13. Linehan, W. M., Srinivasan, R., & Schmidt, L. S. (2010). The genetic basis of kidney cancer: a metabolic disease. Nature Reviews Urology.Google Scholar
  14. Lonser, R. R., Glenn, G. M., Walther, M. C., & Chew, E. Y. (2003). von Hippel-Lindau disease. The Lancet, 361(9374), 2059–2067.CrossRefGoogle Scholar
  15. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): (2016a) Genetic/Familial High-risk Assessment: Breast and Ovarian (Version 2.2016). Available at: https://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf
  16. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): (2016b) Genetic/Familial High-Risk Assessment: Colorectal (Version 1.2016). Available at https://www.nccn.org/professionals/physician_gls/pdf/genetics_colon.pdf
  17. Olshan, A. F., Kuo, T. M., Meyer, A. M., & Nielsen, M. E. (2013). Racial difference in histologic subtype of renal cell carcinoma. Cancer. doi: 10.1002/cam4.110/full.Google Scholar
  18. Patel, N. H., Attwood, K. M., Hanzly, M., Creighton, T. T., Mehedint, D. C., Schwaab, T., & Kauffman, E. C. (2015). Comparative analysis of smoking as a risk factor among renal cell carcinoma histological subtypes. The Journal of Urology, 194(3), 640–646. doi: 10.1016/j.juro.2015.03.125.CrossRefPubMedGoogle Scholar
  19. Pavlovich, C. P., Walther, M. M., Eyler, R. A., Hewitt, S. M., Zbar, B., Linehan, W. M., & Merino, M. J. (2002). Renal tumors in the Birt-Hogg-Dubé syndrome. The American Journal of Surgical Pathology, 26(12), 1542–1552.CrossRefPubMedGoogle Scholar
  20. Reaume, M. N., Graham, G. E., Tomiak, E., Kamel-Reid, S., Jewett, M. A. S., Bjarnason, G. A., et al. (2013). Canadian guideline on genetic screening for hereditary renal cell cancers. Canadian Urological Association Journal = Journal De l'Association Des Urologues Du Canada, 7(9–10), 319–323. doi: 10.5489/cuaj.1496.CrossRefPubMedPubMedCentralGoogle Scholar
  21. Schmidt, L., Junker, K., Nakaigawa, N., Kinjerski, T., Weirich, G., Miller, M., et al. (1999). Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene, 18(14), 2343–2350. doi: 10.1038/sj.onc.1202547.CrossRefPubMedGoogle Scholar
  22. Siegel, R. L., Miller, K. D., & Jemal, A. (2015). Cancer statistics, 2015. CA: a Cancer Journal for Clinicians, 65(1), 5–29. doi: 10.3322/caac.21254.Google Scholar
  23. Störkel, S., Eble, J. N., Adlakha, K., Amin, M., Blute, M. L., Bostwick, D. G., et al. (1997). Classification of renal cell carcinoma: workgroup no. 1. Union Internationale Contre le cancer (UICC) and the American joint committee on cancer (AJCC). Cancer, 80(5), 987–989.CrossRefPubMedGoogle Scholar
  24. Toro, J. R., Wei, M. H., Glenn, G. M., Weinreich, M., Toure, O., Vocke, C., et al. (2008). BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dubé syndrome: a new series of 50 families and a review of published reports. Journal of Medical Genetics, 45(6), 321–331. doi: 10.1136/jmg.2007.054304.CrossRefPubMedPubMedCentralGoogle Scholar
  25. Wei, M. H., Toure, O., Glenn, G. M., Pithukpakorn, M., Neckers, L., Stolle, C., et al. (2006). Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer. Journal of Medical Genetics, 43(1), 18–27. doi: 10.1136/jmg.2005.033506.CrossRefPubMedGoogle Scholar

Copyright information

© National Society of Genetic Counselors, Inc. 2017

Authors and Affiliations

  • Hong Truong
    • 1
  • Sarah E. Hegarty
    • 2
  • Leonard G. Gomella
    • 1
  • William K. Kelly
    • 3
  • Edouard J. Trabulsi
    • 1
  • Costas D. Lallas
    • 1
  • Veda N. Giri
    • 4
  1. 1.Department of Urology, Sidney Kimmel Cancer CenterThomas Jefferson University HospitalPhiladelphiaUSA
  2. 2.Division of Biostatistics, Department of Pharmacology and Experimental TherapeuticsThomas Jefferson University HospitalPhiladelphiaUSA
  3. 3.Department of Medical Oncology, Sidney kimmel Cancer CenterThomas Jefferson UniversityPhiladelphiaUSA
  4. 4.Cancer Risk Assessment and Clinical Cancer Genetics Program, Sidney Kimmel Cancer CenterThomas Jefferson University HospitalPhiladelphiaUSA

Personalised recommendations